TKPHF (Takeda Pharmaceutical Co) Change In Receivables : $-383 Mil (TTM As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Takeda Pharmaceutical Co Change In Receivables?

Takeda Pharmaceutical Co's change in receivables for the quarter that ended in Mar. 2025 was $-93 Mil. It means Takeda Pharmaceutical Co's Accounts Receivable increased by $93 Mil from Dec. 2024 to Mar. 2025 .

Takeda Pharmaceutical Co's change in receivables for the fiscal year that ended in Mar. 2025 was $-396 Mil. It means Takeda Pharmaceutical Co's Accounts Receivable increased by $396 Mil from Mar. 2024 to Mar. 2025 .

Takeda Pharmaceutical Co's Accounts Receivable for the quarter that ended in Mar. 2025 was $4,760 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Takeda Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2025 was 61.46.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Takeda Pharmaceutical Co's liquidation value for the three months ended in Mar. 2025 was $-38,683 Mil.

Takeda Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Takeda Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Change In Receivables Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Change In Receivables

Get a 7-Day Free Trial

-85.70

1,073.51

562.06

100.82

-395.55

Takeda Pharmaceutical Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															493.24	-302.45	-70.20	82.40	-92.94

Takeda Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-383 Mil.

Takeda Pharmaceutical Co (OTCPK:TKPHF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Takeda Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4759.67	/	7067.06	*	91
=	61.46

2. In Ben Graham's calculation of liquidation value, Takeda Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Takeda Pharmaceutical Co's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2721.022	-	49057.311	+	0.75 * 4759.67	+	0.5 * 8166.97
=	-38,683

Takeda Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (OTCPK:TKPHF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

TAK:USA 4502:Japan 4502:Japan 0A87:UK TKDA:Germany TKD:Germany TKD:Germany TKD:Germany TAKP34:Brazil TKD:Austria

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.